Pomerantz LLP is investigating claims on behalf of investors of  Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton ...

Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Staff at the Idaho National Laboratory, a federal nuclear research facility, have been using artificial intelligence from ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...